RISCHIO DI MORTALITA’ PER LA NASH A SECONDA DEL GRADO DI FIBROSI. UNA GRANDE META-ANALISI DA “CLINICAL GASTROENTEROLOGY & HEPATOLOGY” (FREE)

Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis Cheng Han Ng et al. Background & Aims Fibrosis is a key determinant of clinical outcomes in nonalcoholic fatty liver disease (NAFLD), but time-dependent risk of mortality has not been reported in previous meta-analyses. We performed an updated time-to-event meta-analysis…

RIFAXIMINA PER LA MALATTIA EPATICA DA ALCOL. UN EDITORIALE DA “LANCET” (FREE).

Rifaximin-α in alcohol-associated liver disease Chencheng Xie et al Alcohol-associated liver disease is the most common cause of cirrhosis and a leading indication for liver transplantation in the USA and worldwide. A public health concern, the morbidity and mortality of alcohol-associated liver disease has accelerated globally since the COVID-19 pandemic due to rising alcohol consumption.…

LA RIFAXIMINA RIDUCE LA PROGRESSIONE DELLA FIBROSI NELLA MALATTIA EPATICA DA ALCOL ! 1100 MG AL GIORNO PER 18 MESI: RIDUZIONE DEL 20% DI PROGRESSIONE VS PLACEBO odds ratio 0,42 [0·18–0·98]; p=0·044. RCT SU BIOPSIE DA “LANCET” (FREE)

Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial Mads Israelsen et al. Summary Background Alcohol is the leading cause of liver-related mortality worldwide. The gut–liver axis is considered a key driver in alcohol-related liver disease. Rifaximin-α improves gut-barrier function and reduces systemic inflammation in patients…

L’INSUFFICIENZA RENALE NEL CIRROTICO. L’ULTIMA REVISIONE 2023 DAL GRUPPO DI GARCIA-TSAO. DAL “NEW ENGLAND JOURNAL OF MEDICINE” (FREE)

Acute Kidney Injury in Patients with Cirrhosis Mitra K. Nadim, M.D., and Guadalupe Garcia-Tsao Acute kidney injury (AKI) is a common condition in patients with cirrhosis. It occurs in up to 50% of hospitalized patients with cirrhosis and in 58% of such patients in the intensive care unit (ICU).1-5 AKI is associated with high morbidity and mortality…

CARCINOMA EPATOCELLULARE: UNA REVISIONE OPERATIVA 2023 PER GASTROENTEROLOGI, EPATOLOGI E CHIRURGHI. DA “JAMA SURGERY”

Management of Hepatocellular Carcinoma. A Review Zachary J. Brown et al. Abstract Importance  Hepatocellular carcinoma (HCC) is the sixth most common malignancy and fourth leading cause of cancer-related death worldwide. Recent advances in systemic and locoregional therapies have led to changes in many guidelines regarding systemic therapy, as well as the possibility to downstage patients to undergo…

MA I SUPPLEMENTI CON MICRONUTRIENTI FUNZIONANO? UNA GRANDE REVISIONE PER PREVENIRE LA MALATTIA CARDIOVASCOLARE. DA “JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY” (FREE).

Micronutrient Supplementation to Reduce Cardiovascular Risk Peng An et al. ABSTRACT BACKGROUND Healthy dietary patterns are rich in micronutrients, but their influence on cardiovascular disease (CVD) risks has not been systematically quantified. OBJECTIVES The goal of this study was to provide a comprehensive and most up-to-date evidence-based map that systematically quantifies the impact of micronutrients…